Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan
Open accessThe DOI matches its Crossref record; 200 of the 201 references it cites were found in a registry or an index; 161 of the 331 sources its claims cite were checked for support.
Abstract
OBJECTIVE: Obesity is a biologically complex and heterogeneous disease that requires individualized, phenotype- and complication-oriented therapeutic strategies. The introduction of advanced pharmacotherapies, including GLP-1 receptor agonists (GLP-1 RA), dual Glucose-dependent Insulinotropic Polypeptide/Glucagon-like Peptide-1 (GIP/GLP-1) agonists, and emerging triple agonists, has facilitated a shift from weight-centric goals to precision-based obesity care. This review provides a clinical framework for pharmacologic treatment, organized by phenotype, obesity-related complications, age, and behavioral traits. DESIGN: Narrative review of randomized trials, meta-analyses, real-world evidence, and international guidelines through May 2025. Evidence was synthesized across key obesity phenotypes, cardiometabolic, hepatic, renal, mechanical, behavioral, and stratified by life stage, including pediatric, reproductive-age, and older adults, with attention to safety, cost-effectiveness, and special populations. RESULTS: In established Atherosclerotic Cardiovascular Disease, semaglutide significantly reduces major adverse cardiovascular events. Tirzepatide offers cardiometabolic benefits for high-risk people without overt disease. Both agents improve symptoms and function in Heart Failure with Preserved Ejection Fraction, irrespective of glycemia or weight loss. In Chronic Kidney Disease, they decrease albuminuria and eGFR decline. In Metabolic Dysfunction-Associated Steatotic Liver Disease, GLP-1 RAs and GIP/GLP-1 RAs demonstrate marked histological improvements. Mechanical complications such as osteoarthritis and sleep apnea are improved by anti-obesity medications-induced weight loss. GLP-1 RAs and naltrexone/bupropion prove effective against binge and emotional eating. In youths, liraglutide and semaglutide are both approved and effective. Liraglutide and orlistat preserve lean mass alongside resistance training and adequate protein intake in older and sarcopenic people. CONCLUSIONS: An anti-obesity treatment framework focused on both phenotype and complication burden improves the personalization of obesity care and supports clinical decision-making throughout a person’s lifespan.
Overview
CoChat Summary
TL;DR
This is a narrative review that proposes a phenotype- and complication-guided framework for choosing anti-obesity medications and bariatric surgery across the lifespan. It argues that obesity pharmacotherapy should be matched to comorbidities, behavior, age, and cost rather than BMI alone.
Key findings
- The review synthesizes 200 studies after screening 1,296 titles/abstracts and reviewing 212 full texts; no quantitative meta-analysis was performed.
- In established ASCVD, semaglutide 2.4 mg once weekly reduced MACE by 20% (HR 0.80, 95% CI 0.72–0.90) and all-cause mortality by 19% in people with obesity and established ASCVD without diabetes; in HFpEF, semaglutide improved KCCQ-CSS by +7.8 points and 6MWD by +20.3 m.
- In prediabetes, tirzepatide 15 mg once weekly produced 22.5% mean weight loss and a 94% risk reduction in diabetes progression over 72 weeks; in a separate trial, diabetes incidence was 1.3% vs 13.3% with placebo (HR 0.07).
- In MASH, semaglutide and tirzepatide showed major histologic benefits: semaglutide achieved 59% vs 17% MASH resolution in a phase 2 trial and 62.9% vs 34.3% steatohepatitis resolution without worsening fibrosis in ESSENCE; tirzepatide achieved 44%/56%/62% MASH resolution at 5/10/15 mg vs 10% placebo.
Methods
- Narrative review led by a multidisciplinary panel of endocrinologists, pediatricians, registered dietitians, and obesity medicine specialists.
- Literature searched from January 1998 to May 2025 across PubMed/MEDLINE, Scopus, Cochrane CENTRAL, ClinicalTrials.gov, regulatory sources (EMA/FDA), and manual journal searches; included RCTs, meta-analyses, observational studies, guidelines, and expert consensus documents in English.
- Evidence was organized by phenotype, complication, age/life stage, safety, and cost-effectiveness; recommendations were qualitatively labeled “should be preferred,” “may be considered,” or “not recommended,” with no quantitative meta-analysis.
Limitations
- The paper states that direct head-to-head trials between anti-obesity medications are lacking, limiting comparative conclusions.
- It states that behavioral and psychosocial phenotypes are underrepresented in major trials, which constrains generalizability.
- It states that cost-effectiveness models are highly context-specific and may not extrapolate across healthcare systems.
- Evident from the text: this is a narrative review rather than a de novo clinical trial, so conclusions depend on the quality and heterogeneity of the underlying studies (this is evident from the design and synthesis approach).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
140 Valid · 24 Not valid · 150 Not checked · 63 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Approved by FDA/EMA from age 12.”
§ Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan > Stratification in vulnerable ages > 12–18 years
What the sources say
- Disputedcites [113] Weghuber D, Barrett T, Barrientos-Pérez M et al (2022) Once-weekly semaglutide in adolescents with obesity. N Engl J Med 387:2245–2257 36322838 PMC9997064 sourceExperimental — accuracy not yet measured
The paper’s introductory passage in the Abstract > Conclusions section says that, for adolescents aged 12 or older, the FDA had approved liraglutide, orlistat, and phentermine–topiramate, while the EMA had approved only liraglutide. It describes semaglutide 2.4 mg as approved for adults, not adolescents. No page numbers are available in our copy. (LLM, conf=0.89)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Micronutrient optimization, especially with ≥ 800 IU/day of vitamin D and adequate calcium, is important for muscle function and fall prevention [119].”
§ Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan > Stratification in vulnerable ages > Sarcopenic obesity
What the sources say
- Disputedcites [119] Bischoff-Ferrari HA, Vellas B, Rizzoli R et al (2020) Effect of vitamin D supplementation, omega-3 fatty acid supplementation, or a strength-training exercise program on clinical outcomes in older adults: the DO-HEALTH randomized clinical trial. JAMA 324:1855–1868 33170239 PMC7656284 sourceExperimental — accuracy not yet measured
The Conclusions report that 2000 IU/day of vitamin D did not significantly improve physical performance in adults aged 70 or older without major comorbidities, contrary to the claimed muscle-function benefit in this trial population. The paper does not establish that vitamin D plus adequate calcium prevents falls: calcium was not a randomized intervention, and falls were not among the reported primary outcomes (Study Participants; Primary End Points). (LLM, conf=0.78)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“No benefits on hirsutism are to be expected [161].”
§ Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan > Special populations > Polycystic ovary syndrome (PCOS)
What the sources say
- Disputedcites [161] Teede HJ, Tay CT, Laven JJE et al (2023) Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab 108:2447–2469 37580314 PMC10505534 sourceExperimental — accuracy not yet measured
The guideline's recommendation 4.7.2 (Materials and Methods; page not available) says metformin should be considered over inositol for hirsutism, contrary to the categorical claim that no benefit is expected. Recommendations 4.4.1 and 4.4.5 favor oral contraceptives for hirsutism and note that other interventions may be needed, but do not say metformin has no benefit. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“In STEP-HFpEF, semaglutide 2.4 OW improved Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) (+ 7.8 points), 6-minute walk distance (6MWD) (+ 20.3 m), reduced C Reactive Protein (CRP) (−43.5% vs. −7.3%) and body weight (− 13.3% vs. − 2.6%), and showed a lower, though exploratory, HF event rate (HR 0.08; 95% CI 0.00–0.42) [5].”
§ Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan > Cardio renal metabolic complication-based pharmacotherapy > Atheerotic cardiovascular disease (ASCVD) and heart failure (HF)roscl
What the sources say
- Supportedcites [5] Kosiborod MN, Abildstrøm SZ, Borlaug BA et al (2023) Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 389:1069–1084 37622681 source
The Results and Confirmatory Secondary End Points report the cited 7.8-point KCCQ-CSS difference, 20.3-m 6-minute walk difference, CRP reductions of 43.5% versus 7.3%, and weight changes of −13.3% versus −2.6%. Supportive Secondary and Exploratory End Points report fewer adjudicated heart-failure events with semaglutide (HR 0.08; 95% CI, 0.00–0.42). The Conclusions specify that these findings concern patients with HFpEF and obesity. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The LIGHT trial was terminated early; the impact of MACE remains unknown [15].”
§ Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan > Cardio renal metabolic complication-based pharmacotherapy > Atheerotic cardiovascular disease (ASCVD) and heart failure (HF)roscl
What the sources say
- Supportedcites [15] Nissen SE, Wolski KE, Prcela L et al (2016) Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA 315:990–1004 26954408 source
The Discussion states that the LIGHT trial ended prematurely and that its findings could not establish the prespecified noninferiority criterion. The Conclusions state that, because of the early termination, the cardiovascular safety of naltrexone-bupropion remains uncertain. Page numbers were not provided in our copy. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
168 more claims · 72 with their cited sources checked
Create a free account to see all 377 claims and to verify the 27 references still open.
- It may state two separate claims as one. 175
- The quote only partly states this claim. 2
- Probably not a substantial claim. 43
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Naude J, Zentner A, Suresh P et al (2024) Effect of combined GLP-1 analogue and bupropion/naltrexone on weight loss: a retrospective cohort study. Int J Obes (Lond) 48:1118–1125”
Cited work 10.1038/s41366-024-01526-2 · retracted 2025-12-19 · notice 10.1038/s41366-025-02006-x · this paper published 2025-11-10
Citations
Cites
1 retracted
Naude, J., Zentner, A., Suresh, P., Bittman, J., & Khan, N. A. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01526-2 · Cited by 13
RetractedReduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 2×
“The Diabetes Prevention Program showed that metformin 850 mg BID reduced T2D incidence by 31% over 2.8 years, with greater benefits for younger people with higher Body Mass Index (BMI) [24 ].”
InfluentialLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“Based on the MACE reduction observed in SUSTAIN 6 [30], it should be preferred in patients with established ASCVD (secondary prevention).”
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 5×
“Across major trials, women, especially pre - menopausal, tend to experience greater relative weight loss with GLP-1 RAs and dual incretin therapies such as tirz-epatide [2, 3 ].”
InfluentialThe prevalence and correlates of eating disorders in the National Comorbidity Survey Replication
Hudson, J. I., Hiripi, E., Pope, H. G., & Kessler, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.040 · Cited by 4,973
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1600869 · Cited by 2,934 · cited 2×
“These effects were initially established with lifestyle and surgical interventions [72 ], but pharmacotherapy now offers benefits similar to those of additional pleiotropic actions.”
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · cited 2×
“Liraglutide 3.0 mg ~8% weight loss in SCALE Obesity and Prediabetes [12, 74].”
InfluentialAcarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08905-5 · Cited by 2,543
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Effects of Recombinant Leptin Therapy in a Child with Congenital Leptin Deficiency
Farooqi, I. S., Jebb, S. A., Langmack, G., Lawrence, E., Cheetham, C. H., Prentice, A. M., Hughes, I. A., McCamish, M. A., & O'Rahilly, S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909163411204 · Cited by 1,998 · cited 1×
“A 2025 meta-analysis by Silve-rii et al. that pooled 50 randomized trials, GLP-1 RA were people produces marked reductions in appetite and weight, underscoring leptin’s central role in energy balance [153].”
Diamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947 · cited 1×
“Obesity is more prevalent among females with PCOS than in the general population; it contributes to the development of PCOS and worsens [161] its clinical features, primarily due to hyperinsulinemia resulting from insulin resistance, which increases ovarian androgen production [162, 163].”
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Definition and diagnostic criteria of clinical obesity
Rubino, F., Cummings, D. E., Eckel, R. H., Cohen, R. V., Wilding, J. P. H., Brown, W. A., Stanford, F. C., Batterham, R. L., Farooqi, I. S., Farpour-Lambert, N. J., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00316-4 · Cited by 1,811 · cited 1×
“In July the FDA extended damage [94].”
Deutz, N. E. P., Bauer, J. M., Barazzoni, R., Biolo, G., Boirie, Y., Bosy-Westphal, A., Cederholm, T., Cruz-Jentoft, A., Krznariç, Z., Nair, K. S., et al. (2014) · Clinical Nutrition · doi:10.1016/j.clnu.2014.04.007 · Cited by 1,738
Bhaskaran, K., Douglas, I., Forbes, H., dos-Santos-Silva, I., Leon, D. A., & Smeeth, L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60892-8 · Cited by 1,707
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669
Bariatric Surgery and Long-term Cardiovascular Events
Sjöström, L., Peltonen, M., Jacobson, P., Sjöström, C. D., Karason, K., Wedel, H., Ahlin, S., Anveden, Å., Bengtsson, C., Bergmark, G., et al. (2012) · JAMA · doi:10.1001/jama.2011.1914 · Cited by 1,656
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636 · cited 1×
“ORIGIN reported a 1.6 kg gain over 6 years with insulin glargine [46].”
InfluentialBray, G. A., Kim, K. K., Wilding, J. P. H., & on behalf of the World Obesity Federation (2017) · Obesity Reviews · doi:10.1111/obr.12551 · Cited by 1,612
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419 · cited 1×
“In STEP 2, semaglutide 2.4 mg led to 9.6% mean weight loss in people with T2D, as expected, slightly less than in non-diabetic populations; HbA1c reductions of ~ 1.6% and improved insulin sensitivity were observed [29].”
InfluentialHampl, S. E., Hassink, S. G., Skinner, A. C., Armstrong, S. C., Barlow, S. E., Bolling, C. F., Avila Edwards, K. C., Eneli, I., Hamre, R., Joseph, M. M., et al. (2023) · Pediatrics · doi:10.1542/peds.2022-060640 · Cited by 1,389
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174
SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes
Malmstrom, T. K., Miller, D. K., Simonsick, E. M., Ferrucci, L., & Morley, J. E. (2016) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12048 · Cited by 1,155 · cited 1×
“The SARC-F questionnaire is a validated tool for routine screening; a score ≥ 4 indicates probable sarcopenia and warrants further assessment with DXA, BIA, handgrip strength, or gait speed testing [120].”
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M. G., Bugianesi, E., Rinella, M. E., Roden, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2413258 · Cited by 1,115
Preconceptional and maternal obesity: epidemiology and health consequences
Poston, L., Caleyachetty, R., Cnattingius, S., Corvalán, C., Uauy, R., Herring, S., & Gillman, M. W. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30217-0 · Cited by 1,111
Picot, J., Jones, J., Colquitt, J., Gospodarevskaya, E., Loveman, E., Baxter, L., & Clegg, A. (2009) · Health Technology Assessment · doi:10.3310/hta13410 · Cited by 1,066
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064
Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60888-4 · Cited by 1,036
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement
Donini, L. M., Busetto, L., Bischoff, S. C., Cederholm, T., Ballesteros-Pomar, M. D., Batsis, J. A., Bauer, J. M., Boirie, Y., Cruz-Jentoft, A. J., Dicker, D., et al. (2022) · Obesity Facts · doi:10.1159/000521241 · Cited by 1,019 · cited 1×
“Nevertheless, their use in sarcopenic obesity requires concurrent resistance training and nutritional support to mitigate functional decline [122].”
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2410027 · Cited by 1,009 · cited 5×
“In patients with HFpEF and obesity, both semaglutide and tirzepatide improve NYHA class, physical function, and quality of life independent of glycemic control, suggesting a glucose and weight-indepen-dent mechanism linked to anti-inflammatory and hemody - namic effects [ 5, 11].”
InfluentialRubino, F., Nathan, D. M., Eckel, R. H., Schauer, P. R., Alberti, K. G. M. M., Zimmet, P. Z., Del Prato, S., Ji, L., Sadikot, S. M., Herman, W. H., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0236 · Cited by 1,008 · cited 1×
“…intervention, primarily through structured lifestyle modifica - tion rather than pharmacotherapy or surgery, to avert the progression toward metabolic dysfunction and end-organ patients with BMI ≥ 35 regardless of glycemic control and for BMI 30–34.9 when medical therapy is insufficient [ 84].”
InfluentialTirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis
Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401943 · Cited by 1,005
Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation
Iyengar, N. M., Gucalp, A., Dannenberg, A. J., & Hudis, C. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.4283 · Cited by 1,004
Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947
Teede, H. J., Tay, C. T., Laven, J. J. E., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., Redman, L. M., Boyle, J. A., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad463 · Cited by 946
Magkos, F., Fraterrigo, G., Yoshino, J., Luecking, C., Kirbach, K., Kelly, S. C., de las Fuentes, L., He, S., Okunade, A. L., Patterson, B. W., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.02.005 · Cited by 886
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404881 · Cited by 871 · cited 1×
“Benefits were consistent across OSA severity and comorbidities [68].”
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
Garvey, W. T., Frias, J. P., Jastreboff, A. M., le Roux, C. W., Sattar, N., Aizenberg, D., Mao, H., Zhang, S., Ahmad, N. N., Bunck, M. C., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01200-x · Cited by 792
Metformin in polycystic ovary syndrome: systematic review and meta-analysis
Lord, J. M., Flight, I. H. K., & Norman, R. J. (2003) · BMJ · doi:10.1136/bmj.327.7421.951 · Cited by 786 · cited 1×
“Metformin has a near-neutral effect on weight, with one meta-analysis finding no effect [ 164 ] and others finding small reductions in BMI, approximately of −0.77 kg/m² (95%CI: −1.26, − 0.27) compared to placebo after three months of treatment with 1500 mg/day in women with PCOS [165, 166].”
InfluentialSjöström, L., Gummesson, A., Sjöström, C. D., Narbro, K., Peltonen, M., Wedel, H., Bengtsson, C., Bouchard, C., Carlsson, B., Dahlgren, S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70159-7 · Cited by 770
Once-weekly semaglutide in adolescents with obesity
Weghuber, D., Barrett, T., Barrientos-Pérez, M., Gies, I., Hesse, D., Jeppesen, O. K., Kelly, A. S., Mastrandrea, L. D., Sørrig, R., & Arslanian, S. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208601 · Cited by 730 · cited 1×
“73% achieved ≥ 5% weight loss and with significant amelioration of CVD factors (e.g. waist circumference, ALT and HbA1c) and no adverse impact on pubertal development and bone health [113].”
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Kelly, A. S., Auerbach, P., Barrientos-Perez, M., Gies, I., Hale, P. M., Marcus, C., Mastrandrea, L. D., Prabhu, N., & Arslanian, S. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916038 · Cited by 723 · cited 1×
“…percentages of participants achieving ≥ 5% and ≥ 10% Weight loss compared to placebo and the BMI standard-deviation score at week 56 (estimated difference, − 0.22; 95% confidence interval [CI], − 0.37 to − 0.08; P = 0.002) [112], but modest reduction in main CVD factors over 56 weeks of treatment.”
InfluentialApovian, C. M., Aronne, L., Rubino, D., Still, C., Wyatt, H., Burns, C., Kim, D., Dunayevich, E., & for the COR‐II Study Group (2013) · Obesity · doi:10.1002/oby.20309 · Cited by 720
Allison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2416394 · Cited by 634 · cited 2×
“Discon-tinuation for adverse events was 6.1% for tirzepatide versus 8.0% for semaglutide [76].”
InfluentialChanoine, J.-P., Hampl, S., Jensen, C., Boldrin, M., & Hauptman, J. (2005) · JAMA · doi:10.1001/jama.293.23.2873 · Cited by 624
on behalf of the SCALE study group, Blackman, A., Foster, G. D., Zammit, G., Rosenberg, R., Aronne, L., Wadden, T., Claudius, B., Jensen, C. B., & Mignot, E. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.52 · Cited by 583
Mingrone, G., Panunzi, S., De Gaetano, A., Guidone, C., Iaconelli, A., Capristo, E., Chamseddine, G., Bornstein, S. R., & Rubino, F. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32649-0 · Cited by 577
Wadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Perri, M. G., Pi‐Sunyer, F. X., Rock, C. L., Erickson, J. S., et al. (2011) · Obesity · doi:10.1038/oby.2010.147 · Cited by 558
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
Lundgren, J. R., Janus, C., Jensen, S. B. K., Juhl, C. R., Olsen, L. M., Christensen, R. M., Svane, M. S., Bandholm, T., Bojsen-Møller, K. N., Blond, M. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028198 · Cited by 536 · cited 1×
“Liraglutide combined with resistance training and high-protein intake has demonstrated preservation of lean mass and strength, making it a suitable option in this setting [201].”
Syn, N. L., Cummings, D. E., Wang, L. Z., Lin, D. J., Zhao, J. J., Loh, M., Koh, Z. J., Chew, C. A., Loo, Y. E., Tai, B. C., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00591-2 · Cited by 521
Hollander, P., Gupta, A. K., Plodkowski, R., Greenway, F., Bays, H., Burns, C., Klassen, P., Fujioka, K., & for the COR-Diabetes Study Group (2013) · Diabetes Care · doi:10.2337/dc13-0234 · Cited by 501
Clément, K., van den Akker, E., Argente, J., Bahm, A., Chung, W. K., Connors, H., De Waele, K., Farooqi, I. S., Gonneau-Lejeune, J., Gordon, G., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30364-8 · Cited by 492 · cited 2×
“In phase 3 trials, patients with POMC or LEPR deficiency experienced significant weight loss and hunger reduction with favorable safety [108 ].”
Sleep Apnea and Cardiovascular Disease: Lessons From Recent Trials and Need for Team Science
Drager, L. F., McEvoy, R. D., Barbe, F., Lorenzi-Filho, G., & Redline, S. (2017) · Circulation · doi:10.1161/circulationaha.117.029400 · Cited by 465 · cited 1×
“Shared mechanisms, leptin resistance, sympathetic activation, and systemic inflammation, link OSA to cardiometabolic risk [67].”
Tirzepatide for Obesity Treatment and Diabetes Prevention
Jastreboff, A. M., le Roux, C. W., Stefanski, A., Aronne, L. J., Halpern, B., Wharton, S., Wilding, J. P. H., Perreault, L., Zhang, S., Battula, R., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2410819 · Cited by 462
Binge-Eating Disorder: Reward Sensitivity and Brain Activation to Images of Food
Schienle, A., Schäfer, A., Hermann, A., & Vaitl, D. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.09.028 · Cited by 447 · cited 1×
“Neuroimaging studies reveal dysfunction in corticostriatal-limbic pathways, particularly in the orbitofrontal cortex, nucleus accumbens, and insula [132, 133].”
Wadden, T. A., Chao, A. M., Machineni, S., Kushner, R., Ard, J., Srivastava, G., Halpern, B., Zhang, S., Chen, J., Bunck, M. C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02597-w · Cited by 442 · cited 1×
“Tirzepatide Tirzepatide led to improved quality of life scores in SURMOUNT-3 [136].”
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
Bliddal, H., Bays, H., Czernichow, S., Uddén Hemmingsson, J., Hjelmesæth, J., Hoffmann Morville, T., Koroleva, A., Skov Neergaard, J., Vélez Sánchez, P., Wharton, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403664 · Cited by 440
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419 · cited 1×
“Preclinical data suggest GIP agonism may reduce stress-induced food seeking [137].”
Stress and Obesity: Are There More Susceptible Individuals?
van der Valk, E. S., Savas, M., & van Rossum, E. F. C. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0306-y · Cited by 402
Häring, H.-U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Broedl, U. C., Woerle, H. J., & on behalf of the EMPA-REG MET Trial Investigators (2014) · Diabetes Care · doi:10.2337/dc13-2105 · Cited by 400
Lee, Y., Doumouras, A. G., Yu, J., Brar, K., Banfield, L., Gmora, S., Anvari, M., & Hong, D. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.10.017 · Cited by 371 · cited 1×
“However, 12% of patients developed new or worsening liver disease, particularly fibrosis [ 87].”
Flemons, W. W. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp012849 · Cited by 362
Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity
Aminian, A., Wilson, R., Al-Kurd, A., Tu, C., Milinovich, A., Kroh, M., Rosenthal, R. J., Brethauer, S. A., Schauer, P. R., Kattan, M. W., et al. (2022) · JAMA · doi:10.1001/jama.2022.9009 · Cited by 357
Bischoff-Ferrari, H. A., Vellas, B., Rizzoli, R., Kressig, R. W., da Silva, J. A. P., Blauth, M., Felson, D. T., McCloskey, E. V., Watzl, B., Hofbauer, L. C., et al. (2020) · JAMA · doi:10.1001/jama.2020.16909 · Cited by 353
Frias, J. P., Deenadayalan, S., Erichsen, L., Knop, F. K., Lingvay, I., Macura, S., Mathieu, C., Pedersen, S. D., & Davies, M. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01163-7 · Cited by 334
Comparative Effectiveness and Safety of Bariatric Procedures for Weight Loss: A PCORnet Cohort Study
Arterburn, D., Wellman, R., Emiliano, A., Smith, S. R., Odegaard, A. O., Murali, S., Williams, N., Coleman, K. J., Courcoulas, A., Coley, R. Y., et al. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2786 · Cited by 317
Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management
Wei, S., Nguyen, T. T., Zhang, Y., Ryu, D., & Gariani, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1185221 · Cited by 291 · cited 1×
“Men, by contrast, often present with higher visceral adiposity and sarcopenic risk, which may attenuate weight loss and predispose to muscle loss during high-efficacy phar - macotherapy [181].”
Nissen, S. E., Wolski, K. E., Prcela, L., Wadden, T., Buse, J. B., Bakris, G., Perez, A., & Smith, S. R. (2016) · JAMA · doi:10.1001/jama.2016.1558 · Cited by 273
Pediatric obesity—Long‐term consequences and effect of weight loss
Marcus, C., Danielsson, P., & Hagman, E. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13547 · Cited by 267 · cited 1×
“These effects persist throughout life unless weight normalization occurs before puberty [97].”
Richette, P., Poitou, C., Garnero, P., Vicaut, E., Bouillot, J.-L., Lacorte, J.-M., Basdevant, A., Clément, K., Bardin, T., & Chevalier, X. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.134015 · Cited by 254
Review: Metabolic Regulation of Inflammation in Osteoarthritis
Berenbaum, F., Griffin, T. M., & Liu‐Bryan, R. (2017) · Arthritis & Rheumatology · doi:10.1002/art.39842 · Cited by 245
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Colhoun, H. M., Lingvay, I., Brown, P. M., Deanfield, J., Brown-Frandsen, K., Kahn, S. E., Plutzky, J., Node, K., Parkhomenko, A., Rydén, L., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03015-5 · Cited by 238
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Garvey, W. T., Blüher, M., Osorto Contreras, C. K., Davies, M. J., Winning Lehmann, E., Pietiläinen, K. H., Rubino, D., Sbraccia, P., Wadden, T., Zeuthen, N., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502081 · Cited by 238
Leiter, L. A., Yoon, K.-H., Arias, P., Langslet, G., Xie, J., Balis, D. A., Millington, D., Vercruysse, F., Canovatchel, W., & Meininger, G. (2015) · Diabetes Care · doi:10.2337/dc13-2762 · Cited by 227
Weight Regain After Bariatric Surgery: Scope of the Problem, Causes, Prevention, and Treatment
Noria, S. F., Shelby, R. D., Atkins, K. D., Nguyen, N. T., & Gadde, K. M. (2023) · Current Diabetes Reports · doi:10.1007/s11892-023-01498-z · Cited by 223
Acosta, A., Camilleri, M., Abu Dayyeh, B., Calderon, G., Gonzalez, D., McRae, A., Rossini, W., Singh, S., Burton, D., & Clark, M. M. (2021) · Obesity · doi:10.1002/oby.23120 · Cited by 222 · cited 2×
“Similarly, older adults with sarcopenic obesity may benefit from agents that help preserve lean mass or combine safely with resistance training [7].”
Garvey, W. T., Ryan, D. H., Henry, R., Bohannon, N. J. V., Toplak, H., Schwiers, M., Troupin, B., & Day, W. W. (2014) · Diabetes Care · doi:10.2337/dc13-1518 · Cited by 215 · cited 1×
“Phentermine/Topiramate ER In a post hoc CONQUER analysis, phentermine/topi-ramate ER reduced T2D progression by 48–78% over 56 weeks, depending on dose and baseline glycemia, driven by up to 10.9% weight loss and improved insulin sensitivity [26].”
InfluentialDiagnosis and treatment of lipodystrophy: a step-by-step approach
Araújo-Vilar, D., & Santini, F. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0887-z · Cited by 194
Is Weight Loss–Induced Muscle Mass Loss Clinically Relevant?
Conte, C., Hall, K. D., & Klein, S. (2024) · JAMA · doi:10.1001/jama.2024.6586 · Cited by 191
Elkind-Hirsch, K. E., Chappell, N., Shaler, D., Storment, J., & Bellanger, D. (2022) · Fertility and Sterility · doi:10.1016/j.fertnstert.2022.04.027 · Cited by 182
Comparison of Combined Bupropion and Naltrexone Therapy for Obesity with Monotherapy and Placebo
Greenway, F. L., Dunayevich, E., Tollefson, G., Erickson, J., Guttadauria, M., Fujioka, K., Cowley, M. A., & for the NB-201 Study Group (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1350 · Cited by 179 · cited 1×
“Secondary analyses show the benefits of binge frequency and global impressions of sever - ity [139].”
McGowan, B. M., Bruun, J. M., Capehorn, M., Pedersen, S. D., Pietiläinen, K. H., Muniraju, H. A. K., Quiroga, M., Varbo, A., & Lau, D. C. W. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00182-7 · Cited by 176
Definitions of Long-Term Weight Regain and Their Associations with Clinical Outcomes
Voorwinde, V., Steenhuis, I. H. M., Janssen, I. M. C., Monpellier, V. M., & van Stralen, M. M. (2020) · Obesity Surgery · doi:10.1007/s11695-019-04210-x · Cited by 174
Wyszyńska, J., Ring-Dimitriou, S., Thivel, D., Weghuber, D., Hadjipanayis, A., Grossman, Z., Ross-Russell, R., Dereń, K., & Mazur, A. (2020) · Frontiers in Pediatrics · doi:10.3389/fped.2020.535705 · Cited by 172
Obesity and upper airway control during sleep
Schwartz, A. R., Patil, S. P., Squier, S., Schneider, H., Kirkness, J. P., & Smith, P. L. (2010) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00919.2009 · Cited by 172
Phentermine/Topiramate for the Treatment of Adolescent Obesity
Kelly, A. S., Bensignor, M. O., Hsia, D. S., Shoemaker, A. H., Shih, W., Peterson, C., & Varghese, S. T. (2022) · NEJM Evidence · doi:10.1056/evidoa2200014 · Cited by 169
Winslow, D. H., Bowden, C. H., DiDonato, K. P., & McCullough, P. A. (2012) · Sleep · doi:10.5665/sleep.2204 · Cited by 163 · cited 1×
“…ER A 28-week RCT showed that mid/high-dose phenter-mine/topiramate in 45 subjects with moderate to severe OSA not on positive airway pressure (PAP) treatment significantly reduced AHI (− 31.5 vs. − 16.6 events/h with pla - cebo; P = 0.0084), with improved oxygenation and sleep quality [70].”
InfluentialCost-Effectiveness of Bariatric Surgery for Severely Obese Adults With Diabetes
Hoerger, T. J., Zhang, P., Segel, J. E., Kahn, H. S., Barker, L. E., & Couper, S. (2010) · Diabetes Care · doi:10.2337/dc10-0554 · Cited by 163
Cardiometabolic characteristics of people with metabolically healthy and unhealthy obesity
Petersen, M. C., Smith, G. I., Palacios, H. H., Farabi, S. S., Yoshino, M., Yoshino, J., Cho, K., Davila-Roman, V. G., Shankaran, M., Barve, R. A., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.03.002 · Cited by 149
Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release
Garvey, W. T., Ryan, D. H., Bohannon, N. J. V., Kushner, R. F., Rueger, M., Dvorak, R. V., & Troupin, B. (2014) · Diabetes Care · doi:10.2337/dc14-0930 · Cited by 149
Bupropion in pregnancy and the prevalence of congenital malformations
Cole, J. A., Modell, J. G., Haight, B. R., Cosmatos, I. S., Stoler, J. M., & Walker, A. M. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1296 · Cited by 149 · cited 1×
“Naltrexone/Bupropion: Crosses the placenta; bupropion has been linked to a small increased risk of cardiac malformations [158].”
Wharton, S., Kuk, J. L., Luszczynski, M., Kamran, E., & Christensen, R. A. G. (2019) · Clinical Obesity · doi:10.1111/cob.12323 · Cited by 144 · cited 1×
“In real-world data, liraglutide 3.0 mg led to meaningful weight loss in patients with prior bariatric procedures, particularly when initiated in the early phase of weight regain [195, 196 ].”
InfluentialCagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Davies, M. J., Bajaj, H. S., Broholm, C., Eliasen, A., Garvey, W. T., le Roux, C. W., Lingvay, I., Lyndgaard, C. B., Rosenstock, J., & Pedersen, S. D. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502082 · Cited by 143
Watanabe, K., Wilmanski, T., Diener, C., Earls, J. C., Zimmer, A., Lincoln, B., Hadlock, J. J., Lovejoy, J. C., Gibbons, S. M., Magis, A. T., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02248-0 · Cited by 143
Liraglutide for Children 6 to <12 Years of Age with Obesity — A Randomized Trial
Fox, C. K., Barrientos-Pérez, M., Bomberg, E. M., Dcruz, J., Gies, I., Harder-Lauridsen, N. M., Jalaludin, M. Y., Sahu, K., Weimers, P., Zueger, T., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2407379 · Cited by 142
Rentzeperi, E., Pegiou, S., Koufakis, T., Grammatiki, M., & Kotsa, K. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030454 · Cited by 140
Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5
Wharton, S., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2023) · Obesity · doi:10.1002/oby.23673 · Cited by 124
Effect of Orlistat in Obese Patients with Binge Eating Disorder
Golay, A., Laurent‐Jaccard, A., Habicht, F., Gachoud, J., Chabloz, M., Kammer, A., & Schutz, Y. (2005) · Obesity Research · doi:10.1038/oby.2005.208 · Cited by 119
Davies, M. J., Aronne, L. J., Caterson, I. D., Thomsen, A. B., Jacobsen, P. B., Marso, S. P., & groups, O. B. O. T. S. A. C. A. –. L. E. I. I. W. A. W. D. (. S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13125 · Cited by 115
MacLaughlin, H. L., Cook, S. A., Kariyawasam, D., Roseke, M., van Niekerk, M., & Macdougall, I. C. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.09.011 · Cited by 102
Hankosky, E. R., Wang, H., Neff, L. M., Kan, H., Wang, F., Ahmad, N. N., Griffin, R., Stefanski, A., & Garvey, W. T. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15318 · Cited by 97
Elkind-Hirsch, K. E., Chappell, N., Seidemann, E., Storment, J., & Bellanger, D. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab408 · Cited by 96
Efficacy of adjuvant weight loss medication after bariatric surgery
Nor Hanipah, Z., Nasr, E. C., Bucak, E., Schauer, P. R., Aminian, A., Brethauer, S. A., & Cetin, D. (2018) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2017.10.002 · Cited by 93
Suliman, M., Buckley, A., Al Tikriti, A., Tan, T., le Roux, C. W., Lessan, N., & Barakat, M. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13672 · Cited by 86 · cited 1×
“In real-world data, liraglutide 3.0 mg led to meaningful weight loss in patients with prior bariatric procedures, particularly when initiated in the early phase of weight regain [195, 196 ].”
InfluentialSemaglutide and cancer: A systematic review and meta-analysis
Nagendra, L., BG, H., Sharma, M., & Dutta, D. (2023) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102834 · Cited by 86
Incidence of end-stage renal disease following bariatric surgery in the Swedish Obese Subjects Study
Shulman, A., Peltonen, M., Sjöström, C. D., Andersson-Assarsson, J. C., Taube, M., Sjöholm, K., le Roux, C. W., Carlsson, L. M. S., & Svensson, P.-A. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0045-x · Cited by 86 · cited 1×
“The SOS study reported reduced end-stage renal disease (ESRD) incidence after surgery (adjusted hazard ratio (HR) = 0.27; 95% CI 0.12–0.60; p = 0.001) [81].”
InfluentialMurvelashvili, N., Xie, L., Schellinger, J. N., Mathew, M. S., Marroquin, E. M., Lingvay, I., Messiah, S. E., & Almandoz, J. P. (2023) · Obesity · doi:10.1002/oby.23736 · Cited by 86
Chao, A. M., Wadden, T. A., Walsh, O. A., Gruber, K. A., Alamuddin, N., Berkowitz, R. I., & Tronieri, J. S. (2019) · Obesity · doi:10.1002/oby.22653 · Cited by 84
Phillips, P., Karrasch, J., Scott, R., Wilson, D., & Moses, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.2.269 · Cited by 82
Gorgojo‐Martínez, J. J., Basagoiti‐Carreño, B., Sanz‐Velasco, A., Serrano‐Moreno, C., & Almodóvar‐Ruiz, F. (2019) · International Journal of Clinical Practice · doi:10.1111/ijcp.13399 · Cited by 82 · cited 1×
“An open-label trial showed greater efficacy than orlistat alone, though gains over liraglutide monotherapy were marginal [188].”
Ghaderi, A., Odeberg, J., Gustafsson, S., Råstam, M., Brolund, A., Pettersson, A., & Parling, T. (2018) · PeerJ · doi:10.7717/peerj.5113 · Cited by 79
Neurobiological features of binge eating disorder
Balodis, I. M., Grilo, C. M., & Potenza, M. N. (2015) · CNS Spectrums · doi:10.1017/s1092852915000814 · Cited by 79 · cited 1×
“Neuroimaging studies reveal dysfunction in corticostriatal-limbic pathways, particularly in the orbitofrontal cortex, nucleus accumbens, and insula [132, 133].”
Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes
Garg, S. K., Kaur, G., Haider, Z., Rodriquez, E., Beatson, C., & Snell-Bergeon, J. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0490 · Cited by 78
Grilo, C. M., & White, M. A. (2013) · Behaviour Research and Therapy · doi:10.1016/j.brat.2013.01.002 · Cited by 78
Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults
Hwang, J. H., Laiteerapong, N., Huang, E. S., & Kim, D. D. (2025) · JAMA Health Forum · doi:10.1001/jamahealthforum.2024.5586 · Cited by 77
Roth, C. L., Scimia, C., Shoemaker, A. H., Gottschalk, M., Miller, J., Yuan, G., Malhotra, S., & Abuzzahab, M. J. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00087-1 · Cited by 76
Bariatric surgery and obstructive sleep apnea: a systematic review and meta-analysis
Al Oweidat, K., Toubasi, A. A., Tawileh, R. B. A., Tawileh, H. B. A., & Hasuneh, M. M. (2023) · Sleep and Breathing · doi:10.1007/s11325-023-02840-1 · Cited by 75
A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder
Allison, K. C., Chao, A. M., Bruzas, M. B., McCuen‐Wurst, C., Jones, E., McAllister, C., Gruber, K., Berkowitz, R. I., Wadden, T. A., & Tronieri, J. S. (2023) · Obesity Science & Practice · doi:10.1002/osp4.619 · Cited by 75
Pharmacological management of binge eating disorder: current and emerging treatment options
McElroy, S., Guerdjikova, A. I., Mori, N., & O’Melia, A. (2012) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s25574 · Cited by 74
Efficacy of orlistat in non‑alcoholic fatty liver disease: A systematic review and meta‑analysis
Wang, H., Wang, L., Cheng, Y., Xia, Z., Liao, Y., & Cao, J. (2018) · Biomedical Reports · doi:10.3892/br.2018.1100 · Cited by 70 · cited 1×
“Benefits were not significant in NASH patients [58 ].”
Jabbour, S. A., Frías, J. P., Ahmed, A., Hardy, E., Choi, J., Sjöström, C. D., & Guja, C. (2020) · Diabetes Care · doi:10.2337/dc19-1350 · Cited by 69 · cited 1×
“Dapagliflozin 10 mg: Dapagliflozin alone caused a 2.7 kg Weight loss after 52 weeks, while combined with exenatide, loss increased to 3.8 kg [41].”
InfluentialRisi, R., Rossini, G., Tozzi, R., Pieralice, S., Monte, L., Masi, D., Castagneto-Gissey, L., Gallo, I. F., Strigari, L., Casella, G., et al. (2022) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2022.03.022 · Cited by 68
Self-citationGLP ‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
Silverii, G. A., Marinelli, C., Bettarini, C., Del Vescovo, G. G., Monami, M., & Mannucci, E. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16489 · Cited by 67
Effect of Orlistat in Obese Patients With Heart Failure: A Pilot Study
Beck‐da‐Silva, L., Higginson, L., Fraser, M., Williams, K., & Haddad, H. (2005) · Congestive Heart Failure · doi:10.1111/j.1527-5299.2005.03827.x · Cited by 64
Graff, S. K., Mario, F. M., Ziegelmann, P., & Spritzer, P. M. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12787 · Cited by 63
Maddaloni, E., Coleman, R. L., Agbaje, O., Buzzetti, R., & Holman, R. R. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30003-6 · Cited by 63
Liu, L., Li, Z., Ye, W., Peng, P., Wang, Y., Wan, L., Li, J., Zhang, M., Wang, Y., Liu, R., et al. (2025) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.103020 · Cited by 62
Kleinendorst, L., Abawi, O., van der Voorn, B., Jongejan, M. H. T. M., Brandsma, A. E., Visser, J. A., van Rossum, E. F. C., van der Zwaag, B., Alders, M., Boon, E. M. J., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0232990 · Cited by 62 · cited 1×
“…> 97th percentile), especially from infancy; (2) Hyperphagia; (3) Family history of early-onset severe obesity in multiple first-degree relatives [ 106]; (4) Associated features: dysmorphisms, developmental delay; (5) Dysmorphic features, developmental delay, or endocri-nopathies (e.g., central…”
Semaglutide in Adults with Type 1 Diabetes and Obesity
Shah, V. N., Akturk, H. K., Kruger, D., Ahmann, A., Bhargava, A., Bakoyannis, G., Pyle, L., & Snell-Bergeon, J. K. (2025) · NEJM Evidence · doi:10.1056/evidoa2500173 · Cited by 62
The relationship between multimorbidity, obesity and functional impairment in older adults
Lynch, D. H., Petersen, C. L., Fanous, M. M., Spangler, H. B., Kahkoska, A. R., Jimenez, D., & Batsis, J. A. (2022) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17683 · Cited by 59 · cited 1×
“It is particularly prevalent among older adults and people with chronic diseases such as T2D, CKD, and cardiovascular disease, and is associated with increased risks of frailty, falls, disability, hospitalization, and mortality [117].”
Goldberg, A., Graca, S., Liu, J., Rao, V., Witchel, S. F., Pena, A., Li, R., Mousa, A., Tay, C. T., Pattuwage, L., et al. (2024) · Obesity Reviews · doi:10.1111/obr.13704 · Cited by 59 · cited 1×
“Obesity is more prevalent among females with PCOS than in the general population; it contributes to the development of PCOS and worsens [161] its clinical features, primarily due to hyperinsulinemia resulting from insulin resistance, which increases ovarian androgen production [162, 163].”
Grilo, C. M., Lydecker, J. A., Morgan, P. T., & Gueorguieva, R. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.10.010 · Cited by 59
Managing obesity in children: a clinical practice guideline
Ball, G. D. C., Merdad, R., Birken, C. S., Cohen, T. R., Goodman, B., Hadjiyannakis, S., Hamilton, J., Henderson, M., Lammey, J., Morrison, K. M., et al. (2025) · Canadian Medical Association Journal · doi:10.1503/cmaj.241456 · Cited by 56
Ladson, G., Dodson, W. C., Sweet, S. D., Archibong, A. E., Kunselman, A. R., Demers, L. M., Lee, P. A., Williams, N. I., Coney, P., & Legro, R. S. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.05.048 · Cited by 56
Argente, J., Verge, C. F., Okorie, U., Fennoy, I., Kelsey, M. M., Cokkinias, C., Scimia, C., Lee, H.-M., & Farooqi, I. S. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00273-0 · Cited by 55
Eckard, A. R., Wu, Q., Sattar, A., Ansari-Gilani, K., Labbato, D., Foster, T., Fletcher, A. A., Adekunle, R. O., & McComsey, G. A. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00150-5 · Cited by 55 · cited 1×
“In a phase 2b randomized placebo-controlled trial, semaglutide 2.4 mg OW significantly reduced abdominal visceral, subcutaneous, and total body fat in people with HIV-associated lipohypertrophy without diabetes [152] (Figs.”
InfluentialCurrent and future pharmacotherapies for obesity in children and adolescents
Kelly, A. S. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00858-9 · Cited by 54 · cited 1×
“Semaglutide currently shows the highest efficacy, followed by liraglutide and phentermine/topiramate [102].”
Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study
Jensterle, M., Ferjan, S., Vovk, A., Battelino, T., Rizzo, M., & Janež, A. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108935 · Cited by 49 · cited 1×
“One study ( n = 25) compared semaglutide 1 mg OW to placebo over 16 weeks, demonstrating greater weight loss with semaglutide (− 5.2 kg versus + 1.9 kg with placebo) [167].”
InfluentialNaltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial
Grilo, C. M., Lydecker, J. A., Jastreboff, A. M., Pittman, B., & McKee, S. A. (2023) · Obesity · doi:10.1002/oby.23898 · Cited by 47
Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents
Lim, F., Bellows, B. K., Tan, S. X., Aziz, Z., Woo Baidal, J. A., Kelly, A. S., & Hur, C. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.29178 · Cited by 42
Cost-Effectiveness of Antiobesity Drugs for Adolescents With Severe Obesity
Mital, S., & Nguyen, H. V. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.36400 · Cited by 41
Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes
Snell-Bergeon, J. K., Kaur, G., Renner, D., Akturk, H. K., Beatson, C., & Garg, S. K. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0328 · Cited by 40
Ardissino, M., Vincent, M., Hines, O., Amin, R., Eichhorn, C., Tang, A. R., Collins, P., Moussa, O., & Purkayastha, S. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa133 · Cited by 40
Risk of colorectal cancer after initiation of orlistat: matched cohort study
Hong, J.-L., Meier, C. R., Sandler, R. S., Jick, S. S., & Sturmer, T. (2013) · BMJ · doi:10.1136/bmj.f5039 · Cited by 38
Cost-effectiveness of a primary care intervention to treat obesity
Tsai, A. G., Wadden, T. A., Volger, S., Sarwer, D. B., Vetter, M., Kumanyika, S., Berkowitz, R. I., Diewald, L. K., Perez, J., Lavenberg, J., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.94 · Cited by 37 · cited 1×
“Interventions are considered cost-effective if their incremental cost-effective - ness ratio (ICER) is below $50,000–$100,000 per QALY in the U.S. or £20,000–£30,000 in the UK [173, 174].”
Moini, A., Kanani, M., Kashani, L., Hosseini, R., & Hosseini, L. (2015) · Endocrine · doi:10.1007/s12020-014-0426-4 · Cited by 37 · cited 3×
“Orlistat A randomized trial ( n = 86) evaluated the efficacy of orli - stat at a dose of 120 mg three times daily for three months, compared to placebo, both combined with lifestyle intervention [170].”
InfluentialSotagliflozin for patients with type 2 diabetes: A systematic review and meta‐analysis
Avgerinos, I., Karagiannis, T., Kakotrichi, P., Michailidis, T., Liakos, A., Matthews, D. R., Tsapas, A., & Bekiari, E. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14555 · Cited by 37
Autoimmunity in lipodystrophy syndromes
Ceccarini, G., Magno, S., Gilio, D., Pelosini, C., & Santini, F. (2021) · La Presse Médicale · doi:10.1016/j.lpm.2021.104073 · Cited by 34
Glucagon-like peptide-1 receptor agonists and safety in the preconception period
Minis, E., Stanford, F. C., & Mahalingaiah, S. (2023) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000835 · Cited by 34 · cited 1×
“Recombinant leptin therapy in these may improve ovulation, reduce insulin resistance, and lower the risk of gestational diabetes mellitus and hypertensive complications [160].”
Abdalla, M. A., Shah, N., Deshmukh, H., Sahebkar, A., Östlundh, L., Al-Rifai, R. H., Atkin, S. L., & Sathyapalan, T. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221127142 · Cited by 33
Rethinking weight loss treatments as cardiovascular medicine in obesity, a comprehensive review
Tuccinardi, D., Watanabe, M., Masi, D., Monte, L., Meffe, L. B., Cavallari, I., Nusca, A., Maddaloni, E., Gnessi, L., Napoli, N., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae171 · Cited by 32
Self-citationRivera Gutierrez, R., Tama, E., Bechenati, D., Castañeda Hernandez, R., Bennett, P. K., McNally, A. W., Fansa, S., Anazco, D., Acosta, A., & Hurtado Andrade, M. D. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.07.006 · Cited by 31
Bajaj, H. S., Burrows, M., Blavignac, J., Paron, E., Camacho, F., Gould, E., & Barakat, M. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14284 · Cited by 28 · cited 1×
“Some studies suggest modest reductions in hepatic fat and transami-nases, but no histologic data support use [59].”
Vanek, L., Kurnikowski, A., Krenn, S., Mussnig, S., & Hecking, M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15967 · Cited by 28
Hassapidou, M. N., Duncanson, K., Shrewsbury, V. A., Ells, L. J., Mulrooney, H. M., Androutsos, O., Vlassopoulos, A., Rito, A. I., Farpourt, N., Brown, T. J., et al. (2022) · Obesity Facts · doi:10.1159/000527540 · Cited by 28
Brain PET Imaging in Obesity and Food Addiction: Current Evidence and Hypothesis
Iozzo, P., Guiducci, L., Guzzardi, M. A., & Pagotto, U. (2012) · Obesity Facts · doi:10.1159/000338328 · Cited by 27 · cited 1×
“Neu-robiologically, it involves hyperactivity in cortico-limbic circuits, such as the amygdala, insula, and orbitofrontal cortex, which can override satiety signals and drive compulsive intake [123, 124].”
Self-citationKamrul-Hasan, A. B. M., Alam, M. S., Dutta, D., Sasikanth, T., Aalpona, F. T. Z., & Nagendra, L. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2024.2164 · Cited by 27
Antiobesity drugs in early pregnancy and congenital malformations in the offspring
Källén, B. A. J. (2014) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2013.11.008 · Cited by 24
Semaglutide treatment of hypothalamic obesity – a real-life data study
Svendstrup, M., Rasmussen, A. K., Kistorp, C., Klose, M., & Andreassen, M. (2024) · Pituitary · doi:10.1007/s11102-024-01429-5 · Cited by 23
Schiavo, L., Santella, B., Mingo, M., Rossetti, G., Orio, M., Cobellis, L., Maurano, A., Iannelli, A., & Pilone, V. (2025) · Nutrients · doi:10.3390/nu17071216 · Cited by 22
Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes
Heerspink, H. J. L., Friedman, A. N., Bjornstad, P., van Raalte, D. H., Cherney, D., Cao, D., Garcia-Pérez, L.-E., Stefanski, A., Turfanda, I., Bunck, M. C., et al. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000764 · Cited by 20
Stoll, F., Kantowski, T., Laaser, J., Kloiber, U., Plitzko, G., Mann, O., Aberle, J., & Lautenbach, A. (2025) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.02.004 · Cited by 20 · cited 1×
“In a 24-week observational study, tirzepatide resulted in clinically significant weight loss and favorable body composition changes, including reduction of visceral adiposity while largely preserving lean mass [197].”
Zorn, S., de Groot, C. J., Brandt-Heunemann, S., von Schnurbein, J., Abawi, O., Bounds, R., Ruck, L., Guijo, B., Martos-Moreno, G. Á., Nicaise, C., et al. (2025) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(25)00065-3 · Cited by 19
King, W. C., Hinerman, A. S., & White, G. E. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.31593 · Cited by 19
Phan, A., Carette, C., Narjoz, C., Rives‐Lange, C., Rassy, N., Czernichow, S., & Pallet, N. (2025) · Obesity · doi:10.1002/oby.24300 · Cited by 18
Bariatric Surgery Outcomes in Patients with Chronic Kidney Disease
Pané, A., Claro, M. I., Andújar, A. M., Olbeyra, R. P., Romano‐Andrioni, B., Boswell, L., Montagud‐Marrahí, E., Jiménez, A., Ibarzábal, A., Viaplana, J., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12186095 · Cited by 17
Dara, P., Farooqui, Z., Mwale, F., Choe, C., van Wijnen, A. J., & Im, H.-J. (2023) · Biomedicines · doi:10.3390/biomedicines11061620 · Cited by 15
Billeter, A. T., Reiners, B., Seide, S. E., Probst, P., Kalkum, E., Rupp, C., & Müller-Stich, B. P. (2022) · Hepatobiliary Surgery and Nutrition · doi:10.21037/hbsn-21-5 · Cited by 12
Jensterle, M., Kovac, J., Vovk, A., Ferjan, S., Battelino, S., Battelino, T., & Janez, A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf278 · Cited by 12
Tronieri, J. S., Ghanbari, E., Chevinsky, J., LaFata, E. M., Minnick, A. M., Rajpal, S., Wang, S. Y., Burcaw, K., Berkowitz, R. I., & Wadden, T. A. (2025) · Nature Medicine · doi:10.1038/s41591-025-03556-3 · Cited by 12
Unveiling the cost-effectiveness of bariatric surgery: insights from a matched cohort study
Lloyd, S. J.-A., Wall-Wieler, E., Liu, Y., Zheng, F., & LaMasters, T. (2025) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2025.04.004 · Cited by 12
Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis
Amori, R. E., Lau, J., & Pittas, A. G. (2007) · JAMA · doi:10.1001/jama.298.2.194 · Cited by 12
Brush, M., Auh, S., Cochran, E., Tuska, R., Koh, C., Kleiner, D. E., Lightbourne, M., & Brown, R. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae335 · Cited by 10
Pina, L., Nguyen-Lee, J., Wood, G. C., Furey, M. J., Petrick, A. T., & Parker, D. M. (2025) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2025.01.008 · Cited by 9 · cited 1×
“Predictors included sleeve gastrectomy, younger age, and male sex [85].”
Psychosoziale Aspekte der Adipositas-Chirurgie
(2019) · doi:10.1007/978-3-662-57364-8 · Cited by 9
1966-LB: Efficacy and Safety of Semaglutide 7.2 mg in Obesity—STEP UP Trial
WHARTON, S., FREITAS, P., HJELMESÆTH, J., KABISCH, M., KANDLER, K., LINGVAY, I., DE LOS ANGELES QUIROGA, M., ROSENSTOCK, J., & GARVEY, W. T. (. (2025) · Diabetes · doi:10.2337/db25-1966-lb · Cited by 8
Obesity in type 1 diabetes: an overlooked immune-metabolic issue
Maddaloni, E., & Tuccinardi, D. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2351868 · Cited by 8
Self-citationCamajani, E., Masi, D., Spizzichini, M. L., Cori, C., Rossetti, R., Spoltore, M. E., Tuccinardi, D., Lubrano, C., Gnessi, L., Isidori, A. M., et al. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16658 · Cited by 7
Self-citationAbi Mosleh, K., Salameh, Y., Ghusn, W., Jawhar, N., Mundi, M. S., Collazo‐Clavell, M. L., Kendrick, M. L., & Ghanem, O. M. (2024) · Clinical Obesity · doi:10.1111/cob.12689 · Cited by 5
NeuroFAST the Integrated Neurobiology of Food Intake, Addiction and Stress
Mercer, J. G., & Bird, S. P. (2012) · Obesity Facts · doi:10.1159/000338824 · Cited by 4
Long‐term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial
Cosentino, F., Dagogo-Jack, S. E., Frederich, R. C., Cannon, C. P., Cherney, D. Z. I., Mancuso, J. P., Wynant, W., Xing, A., Gantz, I., Cater, N. B., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16050 · Cited by 4
A new stage of European Eating Disorders Review: Let's roll up our sleeves
Herpertz‐Dahlmann, B. (2022) · European Eating Disorders Review · doi:10.1002/erv.2917 · Cited by 1
Impact of setmelanotide on metabolic syndrome risk in patients with POMC and LEPR deficiency
Wabitsch, M., Chung, W., Kuhnen, P., Swain, J., Garrison, J., Touchot, N., Argente, J., & Clement, K. (2024) · Endocrine Abstracts · doi:10.1530/endoabs.99.ep57 · Cited by 1
2049-P: Real-World Assessment of Orlistat and Liraglutide in Patients with Obesity: The XENSOR Study
Martínez, J. J. G., BELEN, B.-C., Sanz‐Velasco, A., Serrano‐Moreno, C., & Ruiz, F. A. (2019) · Diabetes · doi:10.2337/db19-2049-p
Impact of Setmelanotide on Metabolic Syndrome Risk in Patients with POMC and LEPR Deficiency
Wabitsch, M., Chung, W. K., Kühnen, P., Swain, J., Garrison, J. C., Touchot, N., Argente, J., & Clément, K. (2024) · Adipositas - Ursachen, Folgeerkrankungen, Therapie · doi:10.1055/s-0044-1788833
Research works printed but not linked: 2
- Castano GSS (2024) Real-world implications and limitations of GLP-1 prescriptions in adolescents. J Endocr Soc 8(Suppl 1):bae163.1506. 10.1210/jendso/bae163.1506. (PMCID: PMC11454784) · doi:10.1210/jendso/bae163.1506
- Website ICER, Accessed June 17, 2025. [Online]. Available: https://icer.org/news-insights/journal-articles/cost-effectiveness-of-oral-semaglutide-added-to-current-antihyperglycemic-treatment-for-type-2-diabetes
Cited by
Gut microbiome and obesity care: Bridging dietary, surgical, and pharmacological interventions
Masi, D., Watanabe, M., & Clément, K. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102573 · Cited by 25
“172 Beyond their effects on appetite, weight loss, and glycemic control, emerging evidence indicates that GLP-1RAs may modulate the gut microbiota.”
Self-citationAsia at the Epicenter of the Global Cardiometabolic Shift
Khanna, S., Gan, G. C. H., Sindone, A. P., Tromp, J., Butler, J., Foo, R., Nerlekar, N., & Bhat, A. (2026) · JACC Asia · doi:10.1016/j.jacasi.2026.01.001 · Cited by 20
Lempesis, I. G., & Dalamaga, Μ. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100463 · Cited by 8
“Patients with prominent metabolic comorbidities such as MASLD may derive additional benefit from dual GLP-1/glucagon or triple agonist approaches [119 – 121].”
InfluentialWu, X., Yuan, C., Wang, H., Pan, X., Wang, R., Cai, Q., Huang, Y., Ren, J., Kang, J., Cheng, M., et al. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121247 · Cited by 2
Nicoletti, C. F., Lara, F. V.-O. D., & Martinez, J. A. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100690 · Cited by 2
Metadata
- Authors
- Tuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U.
- Affiliations
- Università Campus Bio-Medico (IT)
- Sapienza University of Rome (IT)
- University of Bologna (IT)
- Campus Bio Medico University Hospital (IT)
- Bambino Gesù Children's Hospital (IT)
- Corresponding author
- Tuccinardi, Dario
- Watanabe, Mikiko
- Venue
- Journal of Endocrinological Investigation
- Published
- 2025-11-10
- Volume
- 48
- Issue
- 12
- Pages
- 2761-2798
- ISSN
- 0391-4097 (ISSN-L)
- 1720-8386
- PMC
- PMC12640352
- OpenAlex
- W4416063077
- Semantic Scholar
- bf46b2f618e8d68babaa99cd8a63d006d43a6b66
- Cited by
- 29
- References
- 194
- Citations by year
- 2026: 28 · 2025: 1
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Endocrinological Investigation (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
- Funders
- EUROPEAN UNION (NextGenerationEU, under the Italian Ministry of University and Research (MUR) PRIN 2022 program, Mission 4, Component 1, CUP C53D23006490001.)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- obesity, precision medicine, obesity phenotypes, obesity pharmacotherapy, GLP-1 receptor agonists, GIP/GLP-1 dual agonist, semaglutide, tirzepatide, liraglutide, orlistat, naltrexone/bupropion, cardiometabolic complications, heart failure with preserved ejection fraction, chronic kidney disease, non-alcoholic fatty liver disease, sleep apnea, osteoarthritis, binge eating, emotional eating, childhood obesity, sarcopenia, older adults, weight loss
- MeSH terms
- Tirzepatide, Semaglutide, Humans, Longevity, Obesity, Phenotype, Anti-Obesity Agents, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.